Multiple myeloma epidemiology and survival: A unique malignancy

Area of Science:

• Hematologic Malignancies
• Plasma Cell Dyscrasias

Background:

• Multiple myeloma (MM) is the second most common blood cancer, part of a spectrum of plasma cell disorders.
• MM causes significant morbidity and affects older adults, with higher incidence in African Americans.
• Recent treatment advances have improved survival, but diagnosis and monitoring require further development.

Purpose of the Study:

• To review the evolving epidemiology of multiple myeloma.
• To highlight improvements in MM survival rates.
• To examine health disparities in MM subgroups.

Main Methods:

• Review of current literature on MM epidemiology and treatment.
• Analysis of survival data and treatment outcomes.
• Examination of diagnostic and monitoring advancements.

Main Results:

• Significant improvements in MM survival due to novel therapies like immunomodulatory drugs (ImIDs) and proteasome inhibitors (PIs).
• Advancements in minimal residual disease detection enhance MM monitoring.
• Persistent health disparities observed in specific MM patient populations.

Conclusions:

• Continued advancements in MM treatment and monitoring are crucial.
• Inclusive clinical trials representing diverse populations (minorities, elderly) are essential for generalizable results.
• Addressing health disparities is vital for equitable MM patient outcomes.